Business
TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal™ for Cancer and Receives First Sale in Africa - CORRECTION
TNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal™ for Cancer and Receives First Sale in Africa - CORRECTION.
About this update from Biostax Corp.
[{"type":"text","content":"\n\n\n\nTNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal™ for Cancer and Receives First Sale in Africa - CORRECTION\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nTNI BioTech, Inc. Signs Non-Exclusive Distribution Agreement for Lodonal™ for Cancer and Receives First Sale in Africa - CORRECTION\nPR Newswire\nORLANDO, Fla. and DUBLIN, June 25, 2014\n\n\n\nORLANDO, Fla. and DUBLIN, June 25, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTC-TNIB) (\"TNI BioTech\") earlier today announced that its pharmaceutical sales division, Airmed Biopharma Limited, (\"Airmed\"), a wholly owned Irish Company, has signed a non-exclusive distribution agreement with PanAm Global Logistics, Inc. (\"PanAm\") to market Lodonal™.\n\nIn the press release, TNI BioTech and Airmed reported receipt of an initial purchase order for $150,000 and that by the agreement, PanAm seeks to distribute a minimum of 5,000 pills per month for the balance of the year with sales expected to increase in 2015. In fact, PanAm seeks to distribute a minimum of 5,000 'cartons' per month, or 150,000 pills per month, for the balance of the year with sales expected to increase in 2015.\n\nTNI BioTech and Airmed reiterate that Airmed will deliver the first shipment by July 7, 2014.  TNI BioTech and Airmed reiterate their estimate that the agreement will generate approximately $1,800,000 in revenue in year one of the distribution relationship. TNI BioTech and Airmed thank PanAm for pointing out this correction.\n\nAbout TNI BioTech, Inc.\n\nTNI BioTech is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.\n\nOur proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical program...